Attn ex-Sanofi Reps: Did Novo share this during the interview?

Quote








Anonymous said:
Even if this is true, won't even make a dent to Novo's financial strength. NN has had 40 consecutive quarters of double digit growth. SA hasn't had that in years, let alone 40 consecutive quarters.
Click to expand...

Once again the corp cyber defender dept to the rescue. The crusade to squash free speech and put the corp spin in place is never ending.
 




Anonymous said:
Once again the corp cyber defender dept to the rescue. The crusade to squash free speech and put the corp spin in place is never ending.
Click to expand...

Yup. It's the same poster - always the same response. It's comical to see someone like that always respond with the "40 quarters" line...a corporate robot rat.
 








Anonymous said:
Even if this is true, won't even make a dent to Novo's financial strength. NN has had 40 consecutive quarters of double digit growth. SA hasn't had that in years, let alone 40 consecutive quarters.
Click to expand...

That's right! No need to worry about CV risk...

The most corrupt pharma/medical company just ran into a snag with the FDA.
 




Anonymous said:
https://mm.jpmorgan.com/stp/t/c.do?i=2A970-73A&u=a_p*d_940113.pdf*h_-dgbn7cl

I'm sure they were very transparent, you know, like the way Novo has always operated!

Suckers...
Click to expand...

Yes, we try and make it a point to illegally comment on the status of a drug that is currently under FDA review. And just like you, JP Morgan is simply guessing what the Ad Comm is about and what data they may/may not ask for. Is conjecture about an nonapproved product something most companies discuss during the interview process? No? I didn't think so.
 




Anonymous said:
Yes, we try and make it a point to illegally comment on the status of a drug that is currently under FDA review. And just like you, JP Morgan is simply guessing what the Ad Comm is about and what data they may/may not ask for. Is conjecture about an nonapproved product something most companies discuss during the interview process? No? I didn't think so.
Click to expand...

Don't forget, Novo Nordsik has had 40 consecutive quarters of double digit growth. Eat it.
 








Anonymous said:
Yes, we try and make it a point to illegally comment on the status of a drug that is currently under FDA review. And just like you, JP Morgan is simply guessing what the Ad Comm is about and what data they may/may not ask for. Is conjecture about an nonapproved product something most companies discuss during the interview process? No? I didn't think so.
Click to expand...

No conjecture. The CV risk is right there in the article and your medical group knew the data.

Karma. Novo ginned up the cancer scare with glargine. Now, the FDA is onto the fraud with Tresiba.
 




Anonymous said:
No conjecture. The CV risk is right there in the article and your medical group knew the data.

Karma. Novo ginned up the cancer scare with glargine. Now, the FDA is onto the fraud with Tresiba.
Click to expand...

Someone is still sour grapes they didn't get an interview. Maybe we'll consider giving you one during our next expansion.
 








Anonymous said:
No conjecture. The CV risk is right there in the article and your medical group knew the data.

Karma. Novo ginned up the cancer scare with glargine. Now, the FDA is onto the fraud with Tresiba.
Click to expand...

Has the advisory panel announced the rationale for convening? No? Then, as the orgininal point statet, it's pure conjecture. And I ask again, is guessing why the FDA is calling an advisory panel on an unapproved drug something we're supposed to advertise during interviews? Gimme a break. Sorry you didn't get the interview, numbnuts. Tresiba will stick kick your ass when it gets here.
 




Anonymous said:
Has the advisory panel announced the rationale for convening? No? Then, as the orgininal point statet, it's pure conjecture. And I ask again, is guessing why the FDA is calling an advisory panel on an unapproved drug something we're supposed to advertise during interviews? Gimme a break. Sorry you didn't get the interview, numbnuts. Tresiba will stick kick your ass when it gets here.
Click to expand...

The CV risk means it will do more than kick people's ass - it means more risk of kicking the bucket.

Typical arrogance of a Novo rep...we'll sell a boat load of product, who cares about the CV risk.

It's not a matter of conjecture about the FDA panel, it's about the CV risk in the data.
 




Anonymous said:
The CV risk means it will do more than kick people's ass - it means more risk of kicking the bucket.

Typical arrogance of a Novo rep...we'll sell a boat load of product, who cares about the CV risk.

It's not a matter of conjecture about the FDA panel, it's about the CV risk in the data.
Click to expand...

Gimme a break. That's for the FDA to decide, not NNI. If they approve the drug, then our job is to go sell a shitload of it. If the CV risk is too high, then it won't get approved. Quit trying to pretend that we try to promote drugs that aren't safe. I'm sorry that our company does very well and your doesn't. That doesn't mean we're doing things wrong and you're doing them right. Grow up and realize that some companies have better products and are better run than others. That's why we kick your ass.
 




Ex-Sanofi rep here, you got it there is risk in CV. There is a risk in Cancer for glargine as well. Simple truth is that Novo offered me a 50% increase in bonus payout, a 13% increase in salary, and a shot at making it through a holiday season not having to wait by the phone to find out if I am out of the job, because for 6 years straight that was something you, Sanofi, was not willing to give me! Also, the fact that Lantus is up in 2014 and it is rumored from the RML's that the GLP-1 is not making it market before lantus is up, while even if Tresiba doesn't make it Novo offers more of a true portfolio that gives me something to sell way past 2014.
 




these studies were not powered to evaluate CV risk. The fact that there were 12 CV events amongst 3500 patients studied is really not all that surprising and the fact there were about half as many with the Lantus group could have been coincidence. It wouldn't surprise me if the FDA required Novo to run a post-marketing study or even if it asked for clarification of data but anyone that has ever studied statistics would tell you those results are not significant. Ive seen multiple studies where 3 patients have died on a competitor drug vs 0 for ours - doesn't mean I go out and say "drug XYZ kills people."

Like the previous poster said, this is JP Morgan conjecture. We'll see what the FDA really thinks come November.
 




Funny how the link from the OP appears to be to JP Morgan's institutional client website. Either some reps are making so much money that they have family wealth offices to manage their enormous wealth or the OP is a hedge fund short the stock.

Oh for the days when at least a few people on CP actually sold drugs....
 












Top Bottom
Back
Quote